Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MICHAELA ANDERSON

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1861719536
CMS profile
615693
Location
PHILADELPHIA, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$15.23

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $15.23 1

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Abbott Laboratories $15.23 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MICHAELA ANDERSON

NPI 1861719536 · CMS profile ID 615693

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

PHILADELPHIA, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1861719536?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MICHAELA ANDERSON, NPI 1861719536, CMS profile ID 615693. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1861719536?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). MICHAELA ANDERSON, NPI 1861719536, CMS profile ID 615693. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1861719536?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
MICHAELA ANDERSON, NPI 1861719536, CMS profile ID 615693, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1861719536?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $15.23 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Abbott Laboratories $15.2304/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125310468 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2024 $15.23 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

This record has limited reported data across the program years shown and is not featured in search indexes. The records below are complete; see the methodology for how featured pages are determined.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $174,971.40 45
PY2024 Principal investigator $259,699.57 44
PY2023 Principal investigator $77,161.62 12
PY2022 Principal investigator $3,375.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

45 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 United Therapeutics Corporation $1,641.60 12/24/2025 Covered Recipient Teaching Hospital
Hospital Of The Univ Of Penna
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242381126
Principal investigator 1 United Therapeutics Corporation $2,787.75 12/24/2025 Covered Recipient Teaching Hospital
Hospital Of The Univ Of Penna
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242381132
Principal investigator 1 United Therapeutics Corporation $1,690.24 12/24/2025 Covered Recipient Teaching Hospital
Hospital Of The Univ Of Penna
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242381152
Principal investigator 1 United Therapeutics Corporation $695.00 12/03/2025 Covered Recipient Teaching Hospital
Hospital Of The Univ Of Penna
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242381174
Principal investigator 1 United Therapeutics Corporation $1,251.00 12/03/2025 Covered Recipient Teaching Hospital
Hospital Of The Univ Of Penna
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242381178
Principal investigator 1 United Therapeutics Corporation $1,468.80 11/26/2025 Covered Recipient Teaching Hospital
Hospital Of The Univ Of Penna
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242381124
Principal investigator 1 United Therapeutics Corporation $1,512.32 11/26/2025 Covered Recipient Teaching Hospital
Hospital Of The Univ Of Penna
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242381150
Principal investigator 1 United Therapeutics Corporation $3,806.13 11/26/2025 Covered Recipient Teaching Hospital
Hospital Of The Univ Of Penna
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242381162
Principal investigator 1 United Therapeutics Corporation $4,838.40 11/12/2025 Covered Recipient Teaching Hospital
Hospital Of The Univ Of Penna
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242381142
Principal investigator 1 United Therapeutics Corporation $4,981.76 11/12/2025 Covered Recipient Teaching Hospital
Hospital Of The Univ Of Penna
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242381166
Principal investigator 1 United Therapeutics Corporation $6,629.94 11/12/2025 Covered Recipient Teaching Hospital
Hospital Of The Univ Of Penna
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242381168
Principal investigator 1 United Therapeutics Corporation $13,703.24 10/24/2025 Covered Recipient Teaching Hospital
Hospital Of The Univ Of Penna
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242381186
Principal investigator 1 United Therapeutics Corporation $3,550.50 10/22/2025 Covered Recipient Teaching Hospital
Hospital Of The Univ Of Penna
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242381138
Principal investigator 1 United Therapeutics Corporation $2,010.15 09/10/2025 Covered Recipient Teaching Hospital
Hospital Of The Univ Of Penna
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242381128
Principal investigator 1 United Therapeutics Corporation $4,107.81 08/27/2025 Covered Recipient Teaching Hospital
Hospital Of The Univ Of Penna
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242381140
Principal investigator 1 United Therapeutics Corporation $603.26 08/01/2025 Covered Recipient Teaching Hospital
Hospital Of The Univ Of Penna
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242381170
Principal investigator 1 United Therapeutics Corporation $695.00 08/01/2025 Covered Recipient Teaching Hospital
Hospital Of The Univ Of Penna
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242381172
Principal investigator 1 United Therapeutics Corporation $2,069.00 08/01/2025 Covered Recipient Teaching Hospital
Hospital Of The Univ Of Penna
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242381180
Principal investigator 1 United Therapeutics Corporation $26,047.63 07/23/2025 Covered Recipient Teaching Hospital
Hospital Of The Univ Of Penna
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242381190
Principal investigator 1 United Therapeutics Corporation $3,110.40 07/08/2025 Covered Recipient Teaching Hospital
Hospital Of The Univ Of Penna
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242381136
Principal investigator 1 United Therapeutics Corporation $3,202.56 07/08/2025 Covered Recipient Teaching Hospital
Hospital Of The Univ Of Penna
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242381160
Principal investigator 1 United Therapeutics Corporation $2,862.32 06/25/2025 Covered Recipient Teaching Hospital
Hospital Of The Univ Of Penna
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242381158
Principal investigator 1 United Therapeutics Corporation $2,592.00 06/11/2025 Covered Recipient Teaching Hospital
Hospital Of The Univ Of Penna
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242381130
Principal investigator 1 United Therapeutics Corporation $2,668.80 06/11/2025 Covered Recipient Teaching Hospital
Hospital Of The Univ Of Penna
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242381156
Principal investigator 1 United Therapeutics Corporation $675.00 05/21/2025 Covered Recipient Teaching Hospital
Hospital Of The Univ Of Penna
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242381118
Principal investigator 1 United Therapeutics Corporation $4,501.13 05/21/2025 Covered Recipient Teaching Hospital
Hospital Of The Univ Of Penna
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242381164
Principal investigator 1 United Therapeutics Corporation $1,468.80 05/07/2025 Covered Recipient Teaching Hospital
Hospital Of The Univ Of Penna
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242381122
Principal investigator 1 United Therapeutics Corporation $2,841.75 05/07/2025 Covered Recipient Teaching Hospital
Hospital Of The Univ Of Penna
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242381134
Principal investigator 1 United Therapeutics Corporation $5,862.81 05/07/2025 Covered Recipient Teaching Hospital
Hospital Of The Univ Of Penna
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242381144
Principal investigator 1 United Therapeutics Corporation $1,512.32 04/23/2025 Covered Recipient Teaching Hospital
Hospital Of The Univ Of Penna
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242381148
Principal investigator 1 United Therapeutics Corporation $2,334.12 04/23/2025 Covered Recipient Teaching Hospital
Hospital Of The Univ Of Penna
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242381154
Principal investigator 1 United Therapeutics Corporation $834.00 04/23/2025 Covered Recipient Teaching Hospital
Hospital Of The Univ Of Penna
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242381176
Principal investigator 1 United Therapeutics Corporation $2,085.00 04/23/2025 Covered Recipient Teaching Hospital
Hospital Of The Univ Of Penna
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242381182
Principal investigator 1 United Therapeutics Corporation $8,811.24 04/23/2025 Covered Recipient Teaching Hospital
Hospital Of The Univ Of Penna
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242381184
Principal investigator 1 United Therapeutics Corporation $864.00 04/09/2025 Covered Recipient Teaching Hospital
Hospital Of The Univ Of Penna
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242381120
Principal investigator 1 United Therapeutics Corporation $889.60 04/09/2025 Covered Recipient Teaching Hospital
Hospital Of The Univ Of Penna
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242381146
Principal investigator 1 United Therapeutics Corporation $1,728.00 02/26/2025 Covered Recipient Teaching Hospital
Hospital Of The Univ Of Penna
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242381102
Principal investigator 1 United Therapeutics Corporation $6,699.35 02/26/2025 Covered Recipient Teaching Hospital
Hospital Of The Univ Of Penna
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242381108
Principal investigator 1 United Therapeutics Corporation $1,779.20 02/26/2025 Covered Recipient Teaching Hospital
Hospital Of The Univ Of Penna
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242381110
Principal investigator 1 United Therapeutics Corporation $5,064.39 02/26/2025 Covered Recipient Teaching Hospital
Hospital Of The Univ Of Penna
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242381116
Principal investigator 1 United Therapeutics Corporation $2,851.20 02/12/2025 Covered Recipient Teaching Hospital
Hospital Of The Univ Of Penna
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242381104
Principal investigator 1 United Therapeutics Corporation $3,947.86 02/12/2025 Covered Recipient Teaching Hospital
Hospital Of The Univ Of Penna
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242381106
Principal investigator 1 United Therapeutics Corporation $2,069.71 01/29/2025 Covered Recipient Teaching Hospital
Hospital Of The Univ Of Penna
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242381112
Principal investigator 1 United Therapeutics Corporation $2,935.68 01/29/2025 Covered Recipient Teaching Hospital
Hospital Of The Univ Of Penna
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242381114
Principal investigator 1 United Therapeutics Corporation $16,690.63 01/24/2025 Covered Recipient Teaching Hospital
Hospital Of The Univ Of Penna
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242381188